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Systemic lupus erythematosus (SLE, lupus) is the prototype
of systemic autoimmune disease (AD). Immune system
activation in SLE is characterized by exaggerated B-cell and
T-cell responses and loss of immune tolerance against self-
antigens. Production and defective elimination of antibodies,
circulation and tissue deposition of immune complexes, and
complement and cytokine activation contribute to clinical
manifestations that range from fatigue and joint pain to
severe, life-threatening organ damage [1].
In this special issue, nine papers were selected covering
important topics of the disease from B lymphocytes (e.g.,
autoantibodies and B-cell depletion therapy), immunose-
nescence, and genetics to disease complications such as
cardiovascular disease (CVD), preeclampsia, fatigue, and
depression.
B lymphocytes are the effectors of humoral immunity,
providing defense from pathogens through different func-
tions including antibody production. In the context of ADs,
B lymphocytes play an essential role by not only producing
autoantibodies but also functioning as antigen presenting
cells and as a source of cytokines as pointed out byG. J. Tobo´n
and colleagues, who reviewed the functions of B lymphocytes
in autoimmunity and ADs with a special focus on their
abnormalities in SLE.
We recognize today that disease manifestations are deter-
mined by the diversity of autoantibodies appearing in SLE
[2, 3].This explains the different clinical presentations within
individuals with SLE. In this issue, E. Cozzani and colleagues
reviewed the most important autoantibodies in SLE and
their correlation between immunopathological features and
clinical aspects. Recommendations for determining anti-
nuclear antibodies, anti-double stranded DNA antibodies,
specific antibodies, and validation of methods have been
published elsewhere [4].
Given that autoantibody production is the hallmark
of SLE, it is not surprising that B-cell depletion therapy
is a promising therapeutic option in the management of
SLE. Rituximab (RTX), a chimeric anti-CD20 monoclonal
antibody, has been used off-license in the management of
severe refractory SLE since 2002. In this special issue, F.
Bonilla-Abadı´a and colleagues report the results of a retro-
spective and descriptive observational study of patients with
SLE refractory to conventional treatment who were treated
with RTX as remission induction therapy and maintenance.
They observed a significant reduction in the conventional
immunosuppressive drug dose and the number of relapses
of disease suggesting that RTX could be effective and safe in
patients with SLE refractory to conventional therapy.
An important matter about SLE for 2014 will be the
progress and even release of results of the ongoing trials
with the new biological therapies including epratuzumab,
a humanized anti-CD22 monoclonal antibody, and subcu-
taneous belimumab, a human monoclonal antibody that
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inhibits B-lymphocyte stimulator, as well as the investigator-
initiated trials with RTX (i.e., RITUXILUP and Ring) [5].
Senescence is a normal biological process that occurs in
all organisms and involves a decline in cell functions. In the
context of the immune system, this phenomenon is known
as immunosenescence and refers to the immune function
deregulation. A complete review about this topic is also
presented in this issue.
ADs are observed in genetically susceptible individuals in
whom their clinical expression is modified by permissive and
protective environments occurring over time [6]. A plethora
of new susceptibility genetic variants forADshas emerged.As
per the case of SLE, more than 100 loci have been replicated
by several independent studies thatmodify the risk to acquire
the disease. In this issue, J. E. Molineros and colleagues from
OklahomaMedical Research Foundation report a replication
study in which 22 recently identified SLE susceptibility genes
were strongly associated with Malaysians.
In order to better understand the genetic basis of SLE that
might be due to natural selection, P. S. Ramos and colleagues
report an original study showing positive selection at several
SLE-associated loci. Their results “provide corroborating
evidence in support of recent positive selection as one mech-
anism underlying the elevated population frequency of SLE
risk loci and should stimulate future research that integrates
signals of natural selection to help identify functional SLE risk
alleles.”
Concerning environmental factors involved in SLE
induction, we are surprised each time by novel and modern
factors. One of the last ones belongs to the ASIA (Autoim-
mune Syndrome Induced byAdjuvants). In this sense, human
papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine,
recombinant (Gardasil), which became almost mandatory
in many countries, has aluminum as adjuvant. It is not
surprising that 6 cases of SLE following Gardasil vaccination
were reported recently [7]. Further studies on this topic are
expected to come to light in 2014.
CVD is a major concern in patients with SLE, whose
disease expression varies depending on several factors includ-
ing ancestry. J. Amaya-Amaya and colleagues report a high
rate of CVD in Latin American patients with SLE and
encourage preventive population strategies aimed to facilitate
the suppression of cigarette smoking and coffee consumption
to the tight control of dyslipidemia and other modifiable risk
factors for such complication.
One of the obstetric complications of SLE is preeclamp-
sia. A. Schramm and M. E. B. Clowse, after providing an
overview of the pathogenesis of preeclampsia, preeclampsia
in lupus pregnancies, and previous trials for prevention of
preeclampsia with aspirin treatment, recommend low-dose
aspirin administration for all lupus patients starting prior to
16 weeks of gestation. Further clinical trials are needed to
confirm this recommendation.
Patients with SLE report higher levels of cognitive
difficulties, depression, pain, and fatigue. R. Fonseca and
colleagues report a case-control study in which significant
lower scores in quality-of-life dimensions related to physical
impairment were found in patients with SLE as compared
with controls. Authors suggest that unexplained fatigue in
SLE may signify an early sign of immune activation flare-up.
We hope readers of Autoimmune Diseases will enjoy
this special issue and be encouraged to translate this new
knowledge into practice.
Juan-Manuel Anaya
Yehuda Shoenfeld
Ricard Cervera
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